ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
22.75 USD   +1.07%
06/10ANIKA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Gain Premarket Friday

05/20/2022 | 09:11am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ANIKA THERAPEUTICS, INC. 1.07% 22.75 Delayed Quote.-37.18%
DR. REDDY'S LABORATORIES LIMITED 0.54% 4389.45 End-of-day quote.-10.58%
NASDAQ COMPOSITE 1.75% 11322.24 Real-time Quote.-28.87%
SANOFI 0.64% 97.84 Real-time Quote.9.64%
All news about ANIKA THERAPEUTICS, INC.
06/10ANIKA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matter..
AQ
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
05/20Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Ex..
GL
05/20Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding..
CI
05/20Anika Therapeutics Gets FDA OK for X-Twist Knotless Fixation System
DJ
05/13Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -30,1x
Yield 2022 -
Capitalization 331 M 331 M -
Capi. / Sales 2022 2,14x
Capi. / Sales 2023 1,94x
Nbr of Employees 297
Free-Float 98,1%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 22,75 $
Average target price 37,50 $
Spread / Average Target 64,8%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-37.18%331
CSL LIMITED-5.48%90 967
WUXI BIOLOGICS (CAYMAN) INC.-16.21%44 412
SAMSUNG BIOLOGICS CO.,LTD.-10.85%43 617
BIOGEN INC.-11.40%31 133
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-3.75%28 559